Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy

被引:0
|
作者
Li, Juan [1 ]
Niu, Cuili [1 ]
Zhang, Ling [1 ]
Mu, Yanmin [1 ]
Gui, Xiuyin [1 ]
机构
[1] Xingtai Third Hosp, Clin Gynecol, Xingtai, Peoples R China
来源
关键词
Cervical cancer; concurrent chemoradiotherapy; systemic inflammation; body composition; prognosis; VISCERAL FAT PERCENTAGE; PROGNOSTIC VALUE; SARCOPENIA; OBESITY; PREDICTION; MARKERS; CELLS;
D O I
10.4274/dir.2024.242751
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Systemic inflammation and body composition are associated with survival outcomes of cancer patients. This study aimed to examine the combined prognostic value of systemic inflammatory markers and body composition parameters in patients with locally advanced cervical cancer (LACC). METHODS Patients who underwent concurrent chemoradiotherapy (CCRT) for LACC at a tertiary referral teaching hospital between January 2010 and January 2018 were enrolled. A predictive model was established based on systemic immune-inflammation index (SII) and computer tomography-derived visceral fat-to-muscle ratio (vFMR). Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox regression models. The model performance was assessed using discrimination, calibration, and clinical usefulness. RESULTS In total, 212 patients were enrolled. The SII and vFMR were closely related, and both independently predicted survival (P < 0.05). A predictive model was established based on the above biomarkers and included three subgroups: high-risk [both high SII (>828) and high vFMR (>1.1)], middle-risk (either high SII or high vFMR), and low-risk (neither high SII nor high vFMR). The 3-year OS (PFS) rates for low-, middle-, and high-risk patients were 90.5% (86.0%), 73.9% (58.4%), and 46.8% (36.1%), respectively (P < 0.05). This model demonstrated satisfactory predictive accuracy (area under the curve values for predicting 3-year OS and PFS were 0.704 and 0.718, respectively), good fit (Hosmer-Lemeshow tests: P > 0.05), and clinical usefulness. CONCLUSION Systemic inflammatory markers combined with body composition parameters could independently predict the prognosis of patients with LACC, highlighting the utilization of commonly collected indicators in decision-making processes.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [41] Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy
    Zheng Zeng
    Weiping Wang
    Xiaoliang Liu
    Guangyu Wang
    Kang Ren
    Fuquan Zhang
    Ke Hu
    Clinical and Translational Oncology, 2023, 25 : 2892 - 2900
  • [42] Pretreatment lymphocyte count as independent prognostic factor in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Thiangphak, Ekasak
    Pruegsanusak, Korrawit
    Buhachat, Rakchai
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 159 (03) : 672 - 678
  • [43] Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy
    Shim, Seung-Hyuk
    Lee, Shin-Wha
    Park, Jeong-Yeol
    Kim, Young Seok
    Kim, Dae-Yeon
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    Nam, Joo-Hyun
    GYNECOLOGIC ONCOLOGY, 2013, 128 (01) : 54 - 59
  • [44] Ultrasonic histogram assessment of early response to concurrent chemoradiotherapy in patients with locally advanced cervical cancer: a feasibility study
    Xu, Yan
    Ru, Tong
    Zhu, Lijing
    Liu, Baorui
    Wang, Huanhuan
    Zhu, Li
    He, Jian
    Liu, Song
    Zhou, Zhengyang
    Yang, Xiaofeng
    CLINICAL IMAGING, 2018, 49 : 144 - 149
  • [45] Zimberelimab combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer: Early results of efficacy and safety.
    Lin, Genlai
    Ma, Guifen
    Wang, Sitong
    Xiao, Chunli
    Shi, Tingyan
    Xiang, Libing
    Jiang, Li
    Du, Shisuo
    Zeng, Zhaochong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer
    Kwak, Yoo-Kang
    Lee, Jong Hoon
    Lee, Myung-Ah
    Chun, Hoo-Geun
    Kim, Dong-Goo
    You, Young Kyoung
    Hong, Tae-Ho
    Jang, Hong Seok
    RADIATION ONCOLOGY JOURNAL, 2014, 32 (02): : 49 - 56
  • [47] Comparison of Induction Chemotherapy plus Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy alone in Locally Advanced Cervical Cancer Treated with IMRT and Concurrent Cisplatin
    Chen, S.
    Wang, X.
    Feng, J. C.
    Wei, M.
    Chen, G.
    Yin, P.
    Huang, H.
    Zhang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E480 - E480
  • [48] EVALUATION OF THE EFFECT OF LOW MOLECULAR WEIGHT HEPARINS ON THE OUTCOMES OF CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER PATIENTS
    Matylevich, O.
    Mirilenko, L.
    Sukonko, O.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A84 - A84
  • [49] Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy
    Shim, S.
    Kim, D.
    Lee, S.
    Park, J.
    Kim, J.
    Kim, Y.
    Kim, Y.
    Na, Y.
    Nam, J.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S49 - S50
  • [50] Prognostic value of systemic immune-inflammation index in patients with locally advanced cervical cancer
    Torres-Cisneros, Eduardo Rey
    Hernandez-Barajas, David
    Zayas-Villanueva, Omar Alejandro
    Lara, Jackeline Grace
    Bruni-Guerrero, Carla Renata
    Reyna de la Garza, Roberto Adrian
    Martinez Moyano, Javier Alejandro
    Guerrero-Gonzalez, Marisol Denise
    Mendoza, Ricardo C.
    Gonzalez-Guerrero, Juan Francisco
    Vidal-Gutierrez, Oscar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)